Developer docs
API playgroundTry for free, no card

Search company profiles

RadMD

Full company profile

uuid000eriv

Namestring
RadMD
Legal namestring
RadMD
Websiteurl
rad-md.net
Company typeenum
Private
Founded yearint
2022
Descriptiontext

RadMD is an Imaging Contract Research Organization (iCRO) that delivers specialized medical imaging core lab services to pharmaceutical and biotech sponsors of clinical trials. The company supports trial imaging activities from Phase 1 through Phase 3 and regulatory submission, with documented scale of 1,000+ research sites trained, 700+ trial design and analysis projects, and 50+ regulatory submissions across global authorities (INDs, NDAs, PMAs). Therapeutic area specializations span oncology (particularly early-phase), central nervous system (CNS) disorders, diagnostic imaging agents, and AI validation for imaging algorithms.

The company's offering is structured as a centralized imaging core lab platform. Core capabilities include imaging endpoint design, central image review and analysis, blinded independent central review (BICR)-style assessments, a Reader Group of expert radiologists providing independent blinded reads, and site/reader training aimed at reducing site read errors that inflate trial cost. The technology stack is service-led rather than product-led; the proprietary element is the expert reader network, accumulated imaging protocols, and regulatory submission experience rather than a discrete software platform. AI is present as a validation service line for third-party AI imaging algorithms, not as an internal AI development capability.

RadMD operates a B2B professional services revenue model with enterprise field sales targeting pharma and biotech trial sponsors; pricing is not publicly disclosed and requires direct consultation. The company has a small reported headcount (1-10), suggesting a leveraged model where most reader and analytical work is performed by contracted specialists through the Reader Group. RadMD is privately held and is a subsidiary of Medica Group Ltd, a UK-headquartered medical imaging reporting organization that provides operational infrastructure and a UK delivery location in Hastings, East Sussex. The company is headquartered at 1100 East Hector Street, Suite 450, Conshohocken, PA, with leadership comprising co-founders Kohkan Shamsi and Rick Patt, Chief Commercial Officer Judy Currier, and Chief Compliance Officer David Julyk.

Short descriptiontext

RadMD is a medical imaging contract research organization providing centralized imaging core lab services—including oncology, CNS, diagnostic imaging agents, and AI validation—to pharmaceutical and biotech sponsors of clinical trials. A subsidiary of Medica Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersConshohocken, United States
HQ citystring
Conshohocken
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging core lab, clinical trial imaging, oncology imaging services, CNS imaging assessments, AI imaging validation
Industry3 codes
PRIMARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Clinical Trial Imaging Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Imaging Core Lab Services
TypeProfessional Services
Description

B2B professional services providing medical imaging expertise for clinical trials including imaging endpoint design, image review and analysis, and regulatory submission support

radmdimaging.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RadMD is a medical imaging core lab (iCRO) that provides imaging management solutions for clinical trials conducted by pharmaceutical and biotech sponsors. Its services include imaging endpoint design, centralized image review and analysis, expert radiologist reader assessments, site and reader training, and validation of AI-powered imaging tools, supporting trials from Phase 1 through Phase 3 and global regulatory submission. The company is part of Medica Group Ltd and serves therapeutic areas including oncology, CNS, and diagnostic imaging agents.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduces trial costs by eliminating site read errors that inflate expenses and muddy imaging data results
Product overview1 text field

RadMD operates as a unified medical imaging core lab platform providing end-to-end imaging services for clinical trials. The core offering is the Imaging Core Lab service, supported by specialized therapeutic area modules (Oncology, CNS), diagnostic imaging agent validation, AI validation for imaging tools, and a Reader Group network. Site Training services round out the portfolio by ensuring research sites are properly equipped to capture and submit quality imaging data. Together, these products enable sponsors to centralize imaging endpoint assessment from Phase 1 through Phase 3 and regulatory submission.

Product and service1 record
1Imaging Core Lab
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Medica Group Ltd / Medica Reporting Limited
Strategic tierCoreTypeOthers
Description

RadMD is part of Medica Group, a global medical imaging reporting organization. Medica Group provides operational infrastructure and global scale supporting RadMD's core lab services. The parent company operates from Hastings, East Sussex, UK, providing reporting and imaging services internationally.

radmdimaging.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeEmerging player
Description

Emerging imaging biomarker company focused on tau PET ligands and CNS imaging. Comparable in CNS/neurodegenerative imaging specialization though narrower in therapeutic and service scope than RadMD.

TypeBroad incumbent
Description

Mid-to-large CRO with growing imaging capabilities supporting oncology and specialty trials. Competes for sponsor trial awards where imaging endpoints are integrated with broader clinical operations.

TypeDirect peer
Description

UK-based imaging CRO providing image analysis and central reading services for neurological and oncology clinical trials. Closely comparable specialty iCRO with similar therapeutic-area focus and trial-sponsor customer base.

TypeBroad incumbent
Description

Top-5 global CRO with full-service clinical operations including imaging core lab capabilities. Larger broad incumbent that competes for full-service trial awards where imaging is one component of a broader engagement.

TypeDirect peer
Description

Major imaging core lab and clinical trial technology provider offering BICR, imaging management, and endpoint services. The most direct scaled competitor in the iCRO space across oncology, CNS, and other therapeutic areas.

TypeEmerging player
Description

European imaging CRO providing central reading and quantitative image analysis for clinical trials. Comparable specialty iCRO with similar service model and trial-sponsor customer base.

TypeDirect peer
Description

Public imaging CRO specializing in image management and AI-driven lesion detection for oncology clinical trials. Comparable in oncology imaging focus and integration of AI into trial workflows.

TypeDirect peer
Description

Imaging CRO offering image acquisition, analysis, and quantitative biomarker services for clinical trials. Direct comparable in trial-focused imaging services and translational research offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RadMD

Clinical Trial Imaging Servicesrad-md.net

RadMD is a medical imaging contract research organization providing centralized imaging core lab services—including oncology, CNS, diagnostic imaging agents, and AI validation—to pharmaceutical and biotech sponsors of clinical trials. A subsidiary of Medica Group.

What RadMD does

RadMD is an Imaging Contract Research Organization (iCRO) that delivers specialized medical imaging core lab services to pharmaceutical and biotech sponsors of clinical trials. The company supports trial imaging activities from Phase 1 through Phase 3 and regulatory submission, with documented scale of 1,000+ research sites trained, 700+ trial design and analysis projects, and 50+ regulatory submissions across global authorities (INDs, NDAs, PMAs). Therapeutic area specializations span oncology (particularly early-phase), central nervous system (CNS) disorders, diagnostic imaging agents, and AI validation for imaging algorithms.

The company's offering is structured as a centralized imaging core lab platform. Core capabilities include imaging endpoint design, central image review and analysis, blinded independent central review (BICR)-style assessments, a Reader Group of expert radiologists providing independent blinded reads, and site/reader training aimed at reducing site read errors that inflate trial cost. The technology stack is service-led rather than product-led; the proprietary element is the expert reader network, accumulated imaging protocols, and regulatory submission experience rather than a discrete software platform. AI is present as a validation service line for third-party AI imaging algorithms, not as an internal AI development capability.

RadMD operates a B2B professional services revenue model with enterprise field sales targeting pharma and biotech trial sponsors; pricing is not publicly disclosed and requires direct consultation. The company has a small reported headcount (1-10), suggesting a leveraged model where most reader and analytical work is performed by contracted specialists through the Reader Group. RadMD is privately held and is a subsidiary of Medica Group Ltd, a UK-headquartered medical imaging reporting organization that provides operational infrastructure and a UK delivery location in Hastings, East Sussex. The company is headquartered at 1100 East Hector Street, Suite 450, Conshohocken, PA, with leadership comprising co-founders Kohkan Shamsi and Rick Patt, Chief Commercial Officer Judy Currier, and Chief Compliance Officer David Julyk.

RadMD firmographics

Firmographics
Name
RadMD
Legal name
RadMD
Website
https://rad-md.net
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
RadMD is a medical imaging contract research organization providing centralized imaging core lab services—including oncology, CNS, diagnostic imaging agents, and AI validation—to pharmaceutical and biotech sponsors of clinical trials. A subsidiary of Medica Group.
Ownership category
akta.pro rank

RadMD industry classification

Industry
Product category
Clinical Trial Imaging Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Medical imaging core lab
  • Clinical trial imaging
  • Oncology imaging services
  • CNS imaging assessments
  • AI imaging validation

Where RadMD is headquartered

Location

Headquarters

HQ city
Conshohocken
HQ country
United States
HQ region
North America

Offices2 records

Markets served

RadMD business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Imaging Core Lab Services: B2B professional services providing medical imaging expertise for clinical trials including imaging endpoint design, image review and analysis, and regulatory submission support

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

RadMD product offering

Product offering

Core offering

RadMD is a medical imaging core lab (iCRO) that provides imaging management solutions for clinical trials conducted by pharmaceutical and biotech sponsors. Its services include imaging endpoint design, centralized image review and analysis, expert radiologist reader assessments, site and reader training, and validation of AI-powered imaging tools, supporting trials from Phase 1 through Phase 3 and global regulatory submission. The company is part of Medica Group Ltd and serves therapeutic areas including oncology, CNS, and diagnostic imaging agents.

Product overview

RadMD operates as a unified medical imaging core lab platform providing end-to-end imaging services for clinical trials. The core offering is the Imaging Core Lab service, supported by specialized therapeutic area modules (Oncology, CNS), diagnostic imaging agent validation, AI validation for imaging tools, and a Reader Group network. Site Training services round out the portfolio by ensuring research sites are properly equipped to capture and submit quality imaging data. Together, these products enable sponsors to centralize imaging endpoint assessment from Phase 1 through Phase 3 and regulatory submission.

Differentiator

Problem solved

Functional benefit

Products and services

  • Imaging Core Lab

Quantifiable outcome

  • Reduces trial costs by eliminating site read errors that inflate expenses and muddy imaging data results

Companies that use RadMD

Customer profile

Segments4 records

Ideal customer profiles2 records

RadMD technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

RadMD partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Medica Group Ltd / Medica Reporting LimitedcoreOthersRadMD is part of Medica Group, a global medical imaging reporting organization. Medica Group provides operational infrastructure and global scale supporting RadMD's core lab services. The parent company operates from Hastings, East Sussex, UK, providing reporting and imaging services internationally.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

RadMD competitors and assessment

Company assessment

Emerging players

  • Cerveau Technologies: Emerging imaging biomarker company focused on tau PET ligands and CNS imaging. Comparable in CNS/neurodegenerative imaging specialization though narrower in therapeutic and service scope than RadMD.
  • Pharmtrace: European imaging CRO providing central reading and quantitative image analysis for clinical trials. Comparable specialty iCRO with similar service model and trial-sponsor customer base.

Broad incumbents

  • Medpace Holdings: Mid-to-large CRO with growing imaging capabilities supporting oncology and specialty trials. Competes for sponsor trial awards where imaging endpoints are integrated with broader clinical operations.
  • ICON plc: Top-5 global CRO with full-service clinical operations including imaging core lab capabilities. Larger broad incumbent that competes for full-service trial awards where imaging is one component of a broader engagement.

Direct peers

  • IXICO plc: UK-based imaging CRO providing image analysis and central reading services for neurological and oncology clinical trials. Closely comparable specialty iCRO with similar therapeutic-area focus and trial-sponsor customer base.
  • Clario (formerly Bioclinica): Major imaging core lab and clinical trial technology provider offering BICR, imaging management, and endpoint services. The most direct scaled competitor in the iCRO space across oncology, CNS, and other therapeutic areas.
  • Median Technologies: Public imaging CRO specializing in image management and AI-driven lesion detection for oncology clinical trials. Comparable in oncology imaging focus and integration of AI into trial workflows.
  • inviCRO: Imaging CRO offering image acquisition, analysis, and quantitative biomarker services for clinical trials. Direct comparable in trial-focused imaging services and translational research offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

RadMD social profiles

Digital presence

RadMD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RadMD leadership team

Management profile

Number of profiles

Profiles4 records

RadMD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RadMD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RadMD

What does RadMD do?

RadMD is a medical imaging core lab (iCRO) that provides imaging management solutions for clinical trials conducted by pharmaceutical and biotech sponsors. Its services include imaging endpoint design, centralized image review and analysis, expert radiologist reader assessments, site and reader training, and validation of AI-powered imaging tools, supporting trials from Phase 1 through Phase 3 and global regulatory submission. The company is part of Medica Group Ltd and serves therapeutic areas including oncology, CNS, and diagnostic imaging agents.

Is RadMD a public or private company?

RadMD is a private company. It is classified as corporate owned and is currently operating.

When was RadMD founded?

RadMD was founded in 2022. It employs 11 to 50 people.

Where is RadMD based?

RadMD is headquartered in Conshohocken, United States, in the North America region.

How does RadMD make money?

One revenue line is on record: medical Imaging Core Lab Services.

Who are RadMD's main competitors?

Emerging players on record are Cerveau Technologies and Pharmtrace. Broad incumbents are Medpace Holdings and ICON plc. Direct peers are IXICO plc, Clario (formerly Bioclinica), Median Technologies and inviCRO.

Does RadMD have an API?

No public API is recorded for RadMD.

What industry is RadMD in?

RadMD's product category is Clinical Trial Imaging Services. Its primary akta.pro industry code is HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals